AstraZeneca has inked a development and commercialisation deal with Celgene for its haematology programmed cell death ligand 1 (PD-L1) candidate, MEDI4736.
{iframe}http://www.biopharma-reporter.com/Markets-Regulations/Celgene-in-450m-deal-to-commercialise-AZ-s-anti-PD-L1-candidate{/iframe}